25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

7UM (Ultimovacs) Stock Analysis
Buy, Hold or Sell?

Let's analyze Ultimovacs together

I guess you are interested in Ultimovacs ASA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Ultimovacs’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Ultimovacs’s Price Targets

I'm going to help you getting a better view of Ultimovacs ASA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Ultimovacs ASA

I send you an email if I find something interesting about Ultimovacs ASA.

1. Quick Overview

1.1. Quick analysis of Ultimovacs (30 sec.)










1.2. What can you expect buying and holding a share of Ultimovacs? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.20
Expected worth in 1 year
€-0.28
How sure are you?
13.6%

+ What do you gain per year?

Total Gains per Share
€-0.48
Return On Investment
-47.3%

For what price can you sell your share?

Current Price per Share
€1.01
Expected price per share
€0 - €1.328
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Ultimovacs (5 min.)




Live pricePrice per Share (EOD)
€1.01
Intrinsic Value Per Share
€-2.07 - €-2.31
Total Value Per Share
€-1.87 - €-2.11

2.2. Growth of Ultimovacs (5 min.)




Is Ultimovacs growing?

Current yearPrevious yearGrowGrow %
How rich?$7.8m$33.3m-$15.6m-88.5%

How much money is Ultimovacs making?

Current yearPrevious yearGrowGrow %
Making money-$4.7m-$4.4m-$279.1k-5.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Ultimovacs (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#632 / 908

Most Revenue
#811 / 908

Most Profit
#381 / 908

Most Efficient
#263 / 908
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Ultimovacs?

Welcome investor! Ultimovacs's management wants to use your money to grow the business. In return you get a share of Ultimovacs.

First you should know what it really means to hold a share of Ultimovacs. And how you can make/lose money.

Speculation

The Price per Share of Ultimovacs is €1.006. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ultimovacs.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ultimovacs, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.20. Based on the TTM, the Book Value Change Per Share is €-0.12 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ultimovacs.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-0.30-29.4%-0.14-13.7%-0.14-13.5%-0.12-11.9%-0.12-11.6%
Usd Book Value Change Per Share-0.30-29.6%-0.14-13.4%-0.12-11.6%-0.06-6.4%0.011.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.30-29.6%-0.14-13.4%-0.12-11.6%-0.06-6.4%0.011.0%
Usd Price Per Share0.21-0.47-10.04-7.05-6.76-
Price to Earnings Ratio-0.18--1.31--18.58--15.80--15.41-
Price-to-Total Gains Ratio-0.72--5.72--94.31--65.17--59.47-
Price to Book Ratio0.95-0.90-10.69-5.98-5.64-
Price-to-Total Gains Ratio-0.72--5.72--94.31--65.17--59.47-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.140804
Number of shares876
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.14-0.06
Usd Total Gains Per Share-0.14-0.06
Gains per Quarter (876 shares)-118.28-56.09
Gains per Year (876 shares)-473.13-224.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-473-4830-224-234
20-946-9560-449-458
30-1419-14290-673-682
40-1893-19020-897-906
50-2366-23750-1122-1130
60-2839-28480-1346-1354
70-3312-33210-1571-1578
80-3785-37940-1795-1802
90-4258-42670-2019-2026
100-4731-47400-2244-2250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.022.00.00.0%0.022.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%3.019.00.013.6%3.019.00.013.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%3.019.00.013.6%3.019.00.013.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Ultimovacs ASA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.262-0.119-55%-0.103-61%-0.056-78%0.009-2983%
Book Value Per Share--0.2000.454-56%0.856-77%1.009-80%1.065-81%
Current Ratio--3.6167.349-51%7.000-48%13.537-73%15.584-77%
Debt To Asset Ratio--0.2860.175+64%0.155+84%0.114+151%0.109+163%
Debt To Equity Ratio--0.4020.220+82%0.185+117%0.134+200%0.127+216%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--3751447.75311332044.849-67%299295946.055-99%205321499.595-98%194030457.927-98%
Eps---0.261-0.122-53%-0.120-54%-0.106-59%-0.103-61%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.060-0.099+65%-0.115+93%-0.094+57%-0.094+57%
Free Cash Flow To Equity Per Share---0.060-0.099+65%-0.116+94%-0.042-30%-0.042-30%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---2.307--------
Intrinsic Value_10Y_min---2.066--------
Intrinsic Value_1Y_max---0.390--------
Intrinsic Value_1Y_min---0.383--------
Intrinsic Value_3Y_max---1.050--------
Intrinsic Value_3Y_min---1.005--------
Intrinsic Value_5Y_max---1.565--------
Intrinsic Value_5Y_min---1.463--------
Market Cap20348462.600+68%6516507.95314283676.224-54%304605238.155-98%209091203.610-97%197667282.918-97%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio5.026+81%0.9460.895+6%10.694-91%5.979-84%5.637-83%
Pe Ratio-0.964-431%-0.182-1.312+623%-18.579+10133%-15.800+8602%-15.413+8389%
Price Per Share1.006+81%0.1890.415-54%8.855-98%6.220-97%5.964-97%
Price To Free Cash Flow Ratio-4.206-431%-0.792-0.995+26%-21.122+2567%-18.577+2246%-16.888+2033%
Price To Total Gains Ratio-3.835-431%-0.722-5.720+692%-94.311+12961%-65.173+8926%-59.472+8136%
Quick Ratio---0.007-100%0.138-100%3.046-100%2.835-100%
Return On Assets---0.930-0.325-65%-0.118-87%-0.132-86%-0.124-87%
Return On Equity---1.303-0.433-67%-0.141-89%-0.162-88%-0.152-88%
Total Gains Per Share---0.262-0.119-55%-0.103-61%-0.056-78%0.009-2983%
Usd Book Value--7809095.61217719857.096-56%33394135.251-77%37965562.573-79%38429344.066-80%
Usd Book Value Change Per Share---0.297-0.135-55%-0.117-61%-0.064-78%0.010-2983%
Usd Book Value Per Share--0.2270.515-56%0.971-77%1.144-80%1.208-81%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--4254141.75212850538.859-67%339401602.826-99%232834580.541-98%220030539.289-98%
Usd Eps---0.296-0.138-53%-0.136-54%-0.120-59%-0.117-61%
Usd Free Cash Flow---2332838.491-3859276.797+65%-4505067.627+93%-3562528.518+53%-3238662.289+39%
Usd Free Cash Flow Per Share---0.068-0.112+65%-0.131+93%-0.106+57%-0.106+57%
Usd Free Cash Flow To Equity Per Share---0.068-0.112+65%-0.132+94%-0.048-30%-0.048-30%
Usd Market Cap23075156.588+68%7389720.01916197688.838-54%345422340.068-98%237109424.894-97%224154698.829-97%
Usd Price Per Share1.141+81%0.2150.471-54%10.042-98%7.054-97%6.763-97%
Usd Profit---10174995.873-4748142.483-53%-4468983.066-56%-3983310.388-61%-3804095.844-63%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.297-0.135-55%-0.117-61%-0.064-78%0.010-2983%
 EOD+5 -3MRQTTM+7 -24YOY+8 -235Y+6 -2510Y+6 -25

3.3 Fundamental Score

Let's check the fundamental score of Ultimovacs ASA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.964
Price to Book Ratio (EOD)Between0-15.026
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than13.616
Debt to Asset Ratio (MRQ)Less than10.286
Debt to Equity Ratio (MRQ)Less than10.402
Return on Equity (MRQ)Greater than0.15-1.303
Return on Assets (MRQ)Greater than0.05-0.930
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Ultimovacs ASA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.004
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Ultimovacs ASA

As of March 3, 2025, Ultimovacs ASA acquired by Zelluna Immunotherapy AS. Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

Fundamental data was last updated by Penke on 2025-04-08 00:47:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Ultimovacs earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Ultimovacs to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ €0.00 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ultimovacs ASA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--99.7%+99.7%
TTM--188.1%+188.1%
YOY--199.6%+199.6%
5Y--357.6%+357.6%
10Y--488.5%+488.5%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Ultimovacs is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Ultimovacs to theΒ Biotechnology industry mean.
  • -93.0% Return on Assets means thatΒ Ultimovacs generatedΒ €-0.93 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ultimovacs ASA:

  • The MRQ is -93.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -32.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-93.0%TTM-32.5%-60.5%
TTM-32.5%YOY-11.8%-20.7%
TTM-32.5%5Y-13.2%-19.3%
5Y-13.2%10Y-12.4%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-93.0%-12.3%-80.7%
TTM-32.5%-12.2%-20.3%
YOY-11.8%-12.0%+0.2%
5Y-13.2%-13.4%+0.2%
10Y-12.4%-15.3%+2.9%
4.3.1.3. Return on Equity

Shows how efficient Ultimovacs is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Ultimovacs to theΒ Biotechnology industry mean.
  • -130.3% Return on Equity means Ultimovacs generated €-1.30Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ultimovacs ASA:

  • The MRQ is -130.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -43.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-130.3%TTM-43.3%-87.0%
TTM-43.3%YOY-14.1%-29.2%
TTM-43.3%5Y-16.2%-27.1%
5Y-16.2%10Y-15.2%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-130.3%-16.1%-114.2%
TTM-43.3%-16.2%-27.1%
YOY-14.1%-15.8%+1.7%
5Y-16.2%-19.5%+3.3%
10Y-15.2%-21.7%+6.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Ultimovacs ASA.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Ultimovacs is operatingΒ .

  • Measures how much profit Ultimovacs makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Ultimovacs to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ultimovacs ASA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--188.3%+188.3%
TTM--291.0%+291.0%
YOY--214.8%+214.8%
5Y--368.2%+368.2%
10Y--471.9%+471.9%
4.3.2.2. Operating Ratio

Measures how efficient Ultimovacs is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Ultimovacs ASA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.233-2.233
TTM-3.152-3.152
YOY-3.084-3.084
5Y-5.091-5.091
10Y-6.520-6.520
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Ultimovacs ASA.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Ultimovacs is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.62Β means the company has €3.62 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Ultimovacs ASA:

  • The MRQ is 3.616. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.349. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.616TTM7.349-3.732
TTM7.349YOY7.000+0.349
TTM7.3495Y13.537-6.188
5Y13.53710Y15.584-2.047
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6163.616+0.000
TTM7.3493.893+3.456
YOY7.0004.280+2.720
5Y13.5375.791+7.746
10Y15.5846.182+9.402
4.4.3.2. Quick Ratio

Measures if Ultimovacs is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Ultimovacs to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.00Β means the company can pay off €0.00 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ultimovacs ASA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.007-0.007
TTM0.007YOY0.138-0.131
TTM0.0075Y3.046-3.040
5Y3.04610Y2.835+0.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.920-2.920
TTM0.0073.417-3.410
YOY0.1384.170-4.032
5Y3.0465.727-2.681
10Y2.8356.469-3.634
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Ultimovacs ASA.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of UltimovacsΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Ultimovacs to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29Β means that Ultimovacs assets areΒ financed with 28.6% credit (debt) and the remaining percentage (100% - 28.6%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Ultimovacs ASA:

  • The MRQ is 0.286. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.175. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.286TTM0.175+0.112
TTM0.175YOY0.155+0.019
TTM0.1755Y0.114+0.060
5Y0.11410Y0.109+0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2860.344-0.058
TTM0.1750.344-0.169
YOY0.1550.332-0.177
5Y0.1140.359-0.245
10Y0.1090.384-0.275
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Ultimovacs is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Ultimovacs to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 40.2% means that company has €0.40 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ultimovacs ASA:

  • The MRQ is 0.402. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.220. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.402TTM0.220+0.181
TTM0.220YOY0.185+0.035
TTM0.2205Y0.134+0.086
5Y0.13410Y0.127+0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4020.407-0.005
TTM0.2200.427-0.207
YOY0.1850.402-0.217
5Y0.1340.448-0.314
10Y0.1270.493-0.366
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Ultimovacs generates.

  • Above 15 is considered overpriced butΒ always compareΒ Ultimovacs to theΒ Biotechnology industry mean.
  • A PE ratio of -0.18 means the investor is paying €-0.18Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ultimovacs ASA:

  • The EOD is -0.964. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.182. Based on the earnings, the company is expensive. -2
  • The TTM is -1.312. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.964MRQ-0.182-0.783
MRQ-0.182TTM-1.312+1.130
TTM-1.312YOY-18.579+17.267
TTM-1.3125Y-15.800+14.488
5Y-15.80010Y-15.413-0.387
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.964-1.809+0.845
MRQ-0.182-2.564+2.382
TTM-1.312-3.191+1.879
YOY-18.579-3.323-15.256
5Y-15.800-6.424-9.376
10Y-15.413-7.149-8.264
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ultimovacs ASA:

  • The EOD is -4.206. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.792. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.995. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.206MRQ-0.792-3.414
MRQ-0.792TTM-0.995+0.203
TTM-0.995YOY-21.122+20.127
TTM-0.9955Y-18.577+17.582
5Y-18.57710Y-16.888-1.689
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.206-2.461-1.745
MRQ-0.792-3.566+2.774
TTM-0.995-3.951+2.956
YOY-21.122-4.482-16.640
5Y-18.577-8.693-9.884
10Y-16.888-9.796-7.092
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Ultimovacs is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.95 means the investor is paying €0.95Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Ultimovacs ASA:

  • The EOD is 5.026. Based on the equity, the company is overpriced. -1
  • The MRQ is 0.946. Based on the equity, the company is cheap. +2
  • The TTM is 0.895. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD5.026MRQ0.946+4.080
MRQ0.946TTM0.895+0.051
TTM0.895YOY10.694-9.799
TTM0.8955Y5.979-5.084
5Y5.97910Y5.637+0.342
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.0261.676+3.350
MRQ0.9462.283-1.337
TTM0.8952.457-1.562
YOY10.6942.507+8.187
5Y5.9793.773+2.206
10Y5.6374.321+1.316
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in NOK. All numbers in thousands.

Summary
Total Assets115,863
Total Liabilities33,194
Total Stockholder Equity82,669
 As reported
Total Liabilities 33,194
Total Stockholder Equity+ 82,669
Total Assets = 115,863

Assets

Total Assets115,863
Total Current Assets113,847
Long-term Assets2,016
Total Current Assets
Cash And Cash Equivalents 107,371
Total Current Assets  (as reported)113,847
Total Current Assets  (calculated)107,371
+/- 6,476
Long-term Assets
Property Plant Equipment 2,016
Long-term Assets  (as reported)2,016
Long-term Assets  (calculated)2,016
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities31,482
Long-term Liabilities1,712
Total Stockholder Equity82,669
Total Current Liabilities
Accounts payable 4,819
Other Current Liabilities 21,325
Total Current Liabilities  (as reported)31,482
Total Current Liabilities  (calculated)26,144
+/- 5,338
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt2,094
Long-term Liabilities  (as reported)1,712
Long-term Liabilities  (calculated)2,094
+/- 382
Total Stockholder Equity
Total Stockholder Equity (as reported)82,669
Total Stockholder Equity (calculated)0
+/- 82,669
Other
Capital Stock3,441
Common Stock Shares Outstanding 34,406
Net Invested Capital 82,669
Net Working Capital 82,365
Property Plant and Equipment Gross 2,016



6.2. Balance Sheets Structured

Currency in NOK. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
489,213
478,041
453,293
573,245
543,328
529,717
494,020
466,495
426,531
655,537
601,559
579,253
549,592
509,672
495,182
437,059
387,742
349,039
307,618
252,815
215,786
115,863
115,863215,786252,815307,618349,039387,742437,059495,182509,672549,592579,253601,559655,537426,531466,495494,020529,717543,328573,245453,293478,041489,213
   > Total Current Assets 
420,988
407,611
377,334
493,899
463,323
449,363
417,326
389,954
351,042
582,255
532,115
506,647
477,269
435,579
417,469
360,482
314,256
272,117
231,723
178,130
140,069
113,847
113,847140,069178,130231,723272,117314,256360,482417,469435,579477,269506,647532,115582,255351,042389,954417,326449,363463,323493,899377,334407,611420,988
       Cash And Cash Equivalents 
412,025
399,607
367,686
483,159
453,523
440,925
409,288
381,799
347,804
574,168
523,706
486,338
469,063
425,309
405,528
344,104
300,273
266,559
219,962
170,403
130,999
107,371
107,371130,999170,403219,962266,559300,273344,104405,528425,309469,063486,338523,706574,168347,804381,799409,288440,925453,523483,159367,686399,607412,025
       Short-term Investments 
0
0
0
0
453,523
0
409,288
570
347,804
0
0
10,611
2,189
0
606
0
199
0
961
0
0
0
0009610199060602,18910,61100347,804570409,2880453,5230000
       Net Receivables 
8,501
8,004
8,817
8,803
8,378
7,690
6,881
6,714
2,256
6,450
7,345
8,240
5,016
6,271
9,681
14,579
0
0
0
0
0
0
00000014,5799,6816,2715,0168,2407,3456,4502,2566,7146,8817,6908,3788,8038,8178,0048,501
   > Long-term Assets 
68,225
70,430
75,959
79,345
80,005
80,354
76,694
76,541
75,489
73,282
69,444
72,606
72,322
74,093
77,712
76,577
73,487
76,923
75,895
74,685
75,717
2,016
2,01675,71774,68575,89576,92373,48776,57777,71274,09372,32272,60669,44473,28275,48976,54176,69480,35480,00579,34575,95970,43068,225
       Property Plant Equipment 
4,001
4,059
4,399
3,893
4,040
4,007
3,465
2,958
2,512
2,163
1,900
2,050
1,994
5,664
5,177
4,674
4,172
3,674
3,505
2,981
2,491
2,016
2,0162,4912,9813,5053,6744,1724,6745,1775,6641,9942,0501,9002,1632,5122,9583,4654,0074,0403,8934,3994,0594,001
       Goodwill 
10,473
10,851
11,749
11,578
11,698
11,795
11,295
11,388
11,316
11,031
10,453
10,999
10,993
10,701
11,434
11,358
10,948
11,653
11,538
11,453
11,745
0
011,74511,45311,53811,65310,94811,35811,43410,70110,99310,99910,45311,03111,31611,38811,29511,79511,69811,57811,74910,85110,473
       Intangible Assets 
53,751
55,519
59,811
63,873
64,268
64,551
61,934
62,196
61,661
60,088
57,091
59,557
59,335
57,729
61,101
60,544
58,366
61,596
60,852
60,252
61,480
0
061,48060,25260,85261,59658,36660,54461,10157,72959,33559,55757,09160,08861,66162,19661,93464,55164,26863,87359,81155,51953,751
       Other Assets 
0
1
0
2
-1
1
0
-1
0
0
0
0
1
0
0
1
0
0
0
0
0
0
00000010010000-101-12010
> Total Liabilities 
22,006
33,409
33,716
35,248
33,026
41,337
38,694
43,949
44,737
62,384
44,980
33,476
36,540
60,321
72,032
53,889
59,380
69,647
48,412
35,352
24,777
33,194
33,19424,77735,35248,41269,64759,38053,88972,03260,32136,54033,47644,98062,38444,73743,94938,69441,33733,02635,24833,71633,40922,006
   > Total Current Liabilities 
8,099
20,257
19,561
17,250
15,246
27,467
25,711
31,278
32,548
50,897
34,135
21,761
24,613
45,907
57,398
39,768
46,137
56,109
35,224
22,729
12,327
31,482
31,48212,32722,72935,22456,10946,13739,76857,39845,90724,61321,76134,13550,89732,54831,27825,71127,46715,24617,25019,56120,2578,099
       Accounts payable 
1,895
11,768
10,483
8,671
5,401
8,611
8,323
15,321
4,853
22,555
5,921
6,038
10,527
7,655
21,956
14,021
6,404
11,169
12,822
8,677
4,082
4,819
4,8194,0828,67712,82211,1696,40414,02121,9567,65510,5276,0385,92122,5554,85315,3218,3238,6115,4018,67110,48311,7681,895
       Other Current Liabilities 
4,777
0
5,934
4,417
5,236
9,896
10,596
7,428
8,058
11,320
17,342
6,662
7,464
0
12,842
12,600
20,731
-1
17,147
12,211
3,647
21,325
21,3253,64712,21117,147-120,73112,60012,84207,4646,66217,34211,3208,0587,42810,5969,8965,2364,4175,93404,777
   > Long-term Liabilities 
13,907
13,152
14,155
17,997
17,780
13,870
12,983
12,671
12,189
11,487
10,845
11,715
11,927
14,414
14,634
14,121
13,243
13,538
13,188
12,623
12,450
1,712
1,71212,45012,62313,18813,53813,24314,12114,63414,41411,92711,71510,84511,48712,18912,67112,98313,87017,78017,99714,15513,15213,907
       Capital Lease Obligations Min Short Term Debt
3,434
3,626
3,906
3,501
3,756
3,782
3,343
2,889
2,483
2,085
1,738
1,828
1,796
5,480
5,053
4,615
4,169
3,713
3,576
3,011
2,553
2,094
2,0942,5533,0113,5763,7134,1694,6155,0535,4801,7961,8281,7382,0852,4832,8893,3433,7823,7563,5013,9063,6263,434
       Other Liabilities 
10,473
10,850
11,748
16,532
15,681
11,795
11,295
11,387
11,316
11,031
10,453
11,000
10,993
10,702
0
11,359
0
0
0
0
0
0
00000011,359010,70210,99311,00010,45311,03111,31611,38711,29511,79515,68116,53211,74810,85010,473
> Total Stockholder Equity
467,207
444,632
419,577
537,997
510,302
488,380
455,326
422,546
381,794
593,153
556,579
545,777
513,052
449,351
423,150
383,170
328,362
279,392
259,206
217,463
191,009
82,669
82,669191,009217,463259,206279,392328,362383,170423,150449,351513,052545,777556,579593,153381,794422,546455,326488,380510,302537,997419,577444,632467,207
   Common Stock
2,786
2,786
2,786
3,197
3,197
3,197
3,200
3,200
3,200
3,422
3,422
3,422
3,427
3,440
0
3,440
0
0
0
0
0
0
0000003,44003,4403,4273,4223,4223,4223,2003,2003,2003,1973,1973,1972,7862,7862,786
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
1,413
4,202
9,484
9,878
12,907
15,568
15,385
19,068
21,623
23,210
23,238
34,812
39,012
41,715
0
53,020
0
0
0
0
0
0
00000053,020041,71539,01234,81223,23823,21021,62319,06815,38515,56812,9079,8789,4844,2021,413



6.3. Balance Sheets

Currency in NOK. All numbers in thousands.




6.4. Cash Flows

Currency in NOK. All numbers in thousands.




6.5. Income Statements

Currency in NOK. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in NOK. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-151,259
Operating Income-151,259-151,259
 
Operating Expense (+$)
Research Development88,682
Selling General Administrative11,281
Selling And Marketing Expenses-
Operating Expense151,25999,963
 
Net Interest Income (+$)
Interest Income12,417
Interest Expense-1,385
Other Finance Cost-0
Net Interest Income11,032
 
Pretax Income (+$)
Operating Income-151,259
Net Interest Income11,032
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-212,712-151,259
EBIT - interestExpense = -1,385
-201,061
-199,676
Interest Expense1,385
Earnings Before Interest and Taxes (EBIT)--211,327
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-212,712
Tax Provision--11,651
Net Income From Continuing Ops-201,061-201,061
Net Income-201,061
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--11,032
 

Technical Analysis of Ultimovacs
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ultimovacs. The general trend of Ultimovacs is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ultimovacs's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Ultimovacs Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ultimovacs ASA.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.142 < 1.306 < 1.328.

The bearish price targets are: .

Know someone who trades $7UM? Share this with them.πŸ‘‡

Ultimovacs ASA Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ultimovacs ASA. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ultimovacs ASA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ultimovacs ASA.

Ultimovacs ASA Daily Moving Average Convergence/Divergence (MACD) ChartUltimovacs ASA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ultimovacs ASA. The current adx is .

Ultimovacs ASA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ultimovacs ASA.

Ultimovacs ASA Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ultimovacs ASA.

Ultimovacs ASA Daily Relative Strength Index (RSI) ChartUltimovacs ASA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ultimovacs ASA.

Ultimovacs ASA Daily Stochastic Oscillator ChartUltimovacs ASA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ultimovacs ASA.

Ultimovacs ASA Daily Commodity Channel Index (CCI) ChartUltimovacs ASA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ultimovacs ASA.

Ultimovacs ASA Daily Chande Momentum Oscillator (CMO) ChartUltimovacs ASA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ultimovacs ASA.

Ultimovacs ASA Daily Williams %R ChartUltimovacs ASA Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Ultimovacs ASA.

Ultimovacs ASA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ultimovacs ASA.

Ultimovacs ASA Daily Average True Range (ATR) ChartUltimovacs ASA Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ultimovacs ASA.

Ultimovacs ASA Daily On-Balance Volume (OBV) ChartUltimovacs ASA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ultimovacs ASA.

Ultimovacs ASA Daily Money Flow Index (MFI) ChartUltimovacs ASA Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ultimovacs ASA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-22 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-04 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-05 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-09 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-10 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-11 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-19 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-27 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-30 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-06 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-07 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-09 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-14 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-22 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-30 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-05 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-10 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-12 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-13 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-14 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-17 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-19 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-24 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-25 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-28 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-05 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-12 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-20 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-21 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-25 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-31 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-01 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-07 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Ultimovacs ASA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ultimovacs ASA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.004
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Ultimovacs with someone you think should read this too:
  • Are you bullish or bearish on Ultimovacs? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ultimovacs? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ultimovacs ASA

I send you an email if I find something interesting about Ultimovacs ASA.


Comments

How you think about this?

Leave a comment

Stay informed about Ultimovacs ASA.

Receive notifications about Ultimovacs ASA in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.